“Earnings Breakout Begins Monday: Act Now”

By Travis Johnson, Stock Gumshoe, October 28, 2010

Earlier in the week we took a look at a “short” case for a tech stock, so today I thought I’d spend a few minutes tracking down some of Louis Navellier’s favorite picks to buy on what he predicts will be blockbuster earnings in the days ahead.

Navellier has a bunch of both fans and foes in my readership, from what I can tell, and his picks tend to be the kinds of stocks that do make big moves — though sometimes those moves can be down, of course. His system relies on largely quantitative factors like earnings growth and momentum, analyst upgrades, sales momentum, upside earnings surprises, and other measurable things that tend to indicate a stock that’s going to go up on investor enthusiasm — doesn’t seem to work in every kind of market, of course, but he has certainly had his good years, especially when the momentum picks pegged by his grading system lead big market advances.

So what’s he picking this time? Well, he’s got a handful of them, so I won’t spend much time one each but will try to pick out the names and tickers for you so you can make your own decisions.

Navellier is, as he tends to be, pretty optimistic — particularly about technology. And he thinks you can double your money … here’s how he puts it:

“If you didn’t double your money last earnings season, you’re getting a valuable second chance RIGHT NOW….

“There’s a bold new tech revolution headed your way, and there’s simply no stopping it.

“And it’s about to create a windfall not only for a select group of innovative companies but also for those who invest in them now.”

More or less the same kind of thing he’s said before, of course, but he does provide some rationale:

“The global slowdown has forced all companies to get lean and mean—trading workers for technology—and the difference is creating one of the greatest earnings periods in a decade. “

And he provides a few other reasons for this expected boom, too — including low interest rates that make upping production and corporate M&A easier, the big earnings beats by Intel, Qualcomm and Apple, and the low valuation of many tech companies, particularly the larger ones who are in the S&P 500. Throw in that government and corporate IT spending are both on the rise, and the sector looks pretty compelling to our Mr. Navellier.

But of course, “you’ll have to act fast” (otherwise, what’s the rush to subscribe to his newsletter?) He’d like you to sign up for his Emerging Growth newsletter, which will run you about a thousand dollars a year.

The Gumshoe is on the case to sniff out the five stocks that he actually hints about in this ad, though, so let’s move on to that.

Navellier tells us that “Your Best Move” is to …

“Load up on our five top-rated technology juggernauts NOW.”

“Not only are they making money hand over fist NOW, but they are clearly on their way to repeating their past gains in the next 30 to 90 days.”

So what are they? I thought you’d never ask … we’ll look for them in order:

“Tech Breakout No. 1 has me convinced the future has arrived—it manufactures lasers.

“This company is on the cutting edge of this burgeoning field, developing a number of specialized products. And its lasers can be used in fields that range from microelectronics to heavy manufacturing to scientific research.

“With the company doing the majority of its business outside of the U.S., it’s reaping the rewards of a falling U.S. dollar. Its sales jumped 69% in its fiscal third quarter, and it posted a 32% earnings surprise.”

This one is Coherent (COHR), which makes laser, photonics and other optical-type stuff. Roughly a billion dollar company, and they did have 69% sales growth and a 32% earnings surprise last quarter. Their next report comes out November 4, and if it’s any indication of their sector the similarly-sized laser company II-VI (IIVI) reported a blowout earnings beat on Tuesday that sent the shares up about 10% — the other stock that always comes to mind for me in this group is Rofin Sinar (RSTI), which has also not yet reported earnings but, like II-VI, has sometimes been rumored as a takeover candidate and has higher analyst growth expectations relative to their valuation. I don’t know anything about the distinctions between these businesses, just to be clear. Of the three, COHR has the lowest forward PE multiple at about 16 (the other two are around 19), and all have substantial amounts of net cash on their books.


“Tech Breakout No. 2 is an innovative drugmaker that’s constantly seeking a cheaper way to bring specialty generic pharmaceuticals to patients around the world.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...

“It’s leading the charge to develop drugs that target Parkinson’s disease, epilepsy and other central nervous system disorders. And no matter how ObamaCare pans out, certain drugs will still be in high demand—especially this company’s nervous system treatments.

“Shares have climbed 37% in the past 2 months. Grab this one before it declares earnings November 2, and I guarantee you’ll catch the next 50% rise or you won’t pay a dime.”

And yes, it’s in quotes so that’s Navellier’s guarantee, not mine — I have no idea whether it will rise when it reports earnings on Tuesday … and, of course, his guarantee means he’ll refund your subscription, not that he’ll make you whole if you lose a bunch of money on his idea.

Oh, and the name of this stock? This must be Impax Laboratories (IPXL) — they do report on November 2, they are working in specialty generics, and the stock has gone up by about 37% from their dip down to roughly $16 back in August. And he has teased them before, I don’t think I ever discussed this one here but I did cover it for the Irregulars way back in April. They actually surprised on the downside last time they reported, but before that had beaten estimates by well over 100% for the previous three quarters, they often have lumpy earnings thanks to the relatively short window for “premium priced” generics.

Here’s what I wrote about Impax back in April, just to give you more of an idea about their business:

“I generally agree with Navellier’s thesis for generic drugmakers — they should do well in a world when more people are getting health insurance, and when costs become a bigger issue … especially with the government as a major buyer (that’s in part because, in my opinion, they’ll never go against the Big Pharma lobby by aggressively bargaining for lower prices for government drug buys … but they can push for generics and get lower prices without making the lobbyists fuss as terribly).

“And of course it’s a good time to be a generic drug maker — there are now a huge number of blockbuster drugs set to go generic, including the ones that scare pharma investors and make companies like Pfizer, Eli Lilly, Merck and many others look so dirt cheap (single-digit PE ratios, dividends well above average … and huge drugs that make up sometimes a quarter or a half of their earnings going off patent in the near future). One of the greatest success stories in the pharmaceutical space, after all, has been the giant generic drugmaker Teva, which makes up something like half of the entire Israeli stock market index.

“But Teva is a huge multinational, with a market cap of well over $50 billion … Impax is tiny by comparison, at just about $1 billion, and, thanks in part to the law of large numbers, growing much faster. And they’ve just recently become profitable on a fairly consistent basis, running in the black for 2008 and 2009 on the back of big revenue boosts after years of losses.

“Their focus has historically been on drug delivery — developing proprietary versions of existing drugs with a slow-release formulation, for example — and they also have a pipeline of proprietary compounds for the central nervous system that includes a couple drugs in phase III trials … but the real moneymaking part of the business is Global Pharmaceuticals, the generic drug maker that I think they merged with about ten years ago. As with most generic drugmakers, the sales performance rises and falls on when they can get generic formulations of popular drugs approved and out the door right as the patent expires (‘new generics’ generally get a brief exclusivity period for being the first to get a generic drug approval on a particular drug, and not surprisingly the drug prices drop more later on if more generic versions get approved and released).”

And along with the lumpiness of those earnings comes some stress about future products and when or whether they’ll be profitable — which is why analysts think they’ll earn about $3 this year, but less than $1.50 next year… so don’t let the trailing PE of 6 fool you into thinking this is a rock-solid bargain. It might be, of course, but if the analysts are right they’re trading at about 15 times next year’s earnings, an